Sickle Cell Data Collection Program Brief

Georgia Health Policy Center

Follow this and additional works at: https://scholarworks.gsu.edu/ghpc_briefs

Recommended Citation
https://scholarworks.gsu.edu/ghpc_briefs/205

This Article is brought to you for free and open access by the Georgia Health Policy Center at ScholarWorks @ Georgia State University. It has been accepted for inclusion in GHPC Briefs by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact scholarworks@gsu.edu.
For patients with sickle cell disease (SCD) who lack access to specialists or primary care physicians informed about their condition, health care is often limited to the emergency department (ED). New data from the Sickle Cell Data Collection programs in California and Georgia shows that public payers are responsible for the majority of costs associated with these ED visits. An increased focus on access to high-quality, coordinated care — both preventive and SCD-related — may decrease ED visits and costs, while improving quality of life for this population.

ED Use is Common for Sickle Cell Patients

In 2016, there were a total of 33,630 SCD-related visits to EDs in California and Georgia, including a marked increase in ED visits among patients in early adulthood, as they transition from pediatric to adult care. ED visits for those aged 20 to 39 years accounted for more than half of all ED visits by SCD patients.

While some negative effects of the disease are more likely as patients age (e.g., organ damage and stroke-related disability), this increase in ED visits may also be related to the lack of insurance and access to comprehensive care that adults with SCD commonly experience.
PUBLIC PAYERS FUND MAJORITY OF SCD-RELATED EMERGENCY VISITS

Over the three-year period from 2014 to 2016, data from the Sickle Cell Data Collection programs shows that in both California and Georgia, public payers — Medicare and Medicaid — paid for more than 70% of SCD-related ED costs.

Previous studies have shown that medical expenditures for patients with SCD are considerably higher than similarly insured and similarly aged patients without SCD. Lifetime medical costs for patients with SCD are substantial — $1 million for an SCD patient reaching 45 years of age. Given the high-cost of care, payers are incentivized to find cost-effective means to reduce costly ED visits due to disease crises.

POLICY IMPLICATIONS

It has been shown for other chronic conditions that having a regular doctor and coordinated care — which might include case management, home visits, or telemedicine consultations — can reduce ED visits and cut total medical costs. If the same holds for patients with SCD, these findings suggest a potential for significant savings. Better access to SCD-specific outpatient care that follows evidence-based practice recommendations may improve overall disease management of SCD and decrease reliance on expensive ED services. Policymakers may find these data from the Sickle Cell Data Collection programs helpful as they consider ways to improve SCD patients’ access to outpatient care, to develop coordinated care models for patients with SCD, and to increase SCD expertise among health care providers (through education, workforce incentives, and telemedicine).